Novaliq named Finalist in “Clinical Trial Result of the Year” category of the LifeStars Awards 2019

Heidelberg, Germany – September 10, 2019 – Novaliq is pleased to announce that it has been recognised in the finalist roster of the Clinical Trial of the Year at the 2019 Lifestars AwardsTM.

Lifestars is a celebration of the success stories, innovations, transformational deals and the people, teams and organisations that play such a critical role in the advancement of the industry over the last 12 months across Europe and the US.

In 2018, Novaliq conducted SEECASE-1, a phase 2, multi-center, randomized, double-masked, comparator-controlled clinical trial (NCT03333057) which was designed to evaluate the effects of NOV03 at two different dosing regimens on signs and symptoms of DED.

NOV03 (100% perfluorohexyloctane) stabilizes the lipid layer of the tear film for hours, thereby preventing excessive tear evaporation. Furthermore, NOV03 uniquely penetrates Meibomian glands and potentially dissolve thickened Meibum, thereby improving Meibomian gland function and quality. Patients enrolled were suffering from DED due to significant MGD presence – a very symptomatic and highly underserved population.

In SEECASE-1, NOV03 showed unprecedented sign and symptom improvements for DED patients while offering an excellent safety and tolerability profile; the new mode of action of NOV03 addresses the underlying causes of evaporative DED associated with MGD, thereby treating signs and symptoms of the diseases in a highly effective way.

The international awards brings together hundreds of global life science leaders, investors and deal makers and key stakeholders from the wider eco-system to recognise the achievements of the industry. 17 awards will be contested during a prestigious gala dinner hosted at the Honourable Artillery Company in London, UK on the 19thNovember. The Awards will support Teenage Cancer Trust as the official Charity beneficiary.

“We are pleased being nominated by LSX for a Lifestars Award for our NOV03 Clinical trial showing significant benefits for patients with dry eye disease which is associated with meibomian gland dysfunction.” Sonja Krösser, PhD, VP Preclinical and Clinical Development, Novaliq GmbH.

“Lifestars presents a fantastic opportunity to bring together a deserved audience and highlight the advances being made in our industry. It’s testament to Novaliq efforts that this year’s judging faculty have recognised them in this manner.” Neil Darkes, Co-CEO, LSX Ltd. and LifestarsTM


About LifestarsTM

The LifestarsTM Awards are organised by LSX, an influential community of senior life science decision makers. Through impactful events, powerful thought leadership content and unique networking opportunities, LSX exists to forge a fundamentally better way to promote and facilitate investment, financing, partnerships and deal making in healthcare. For more information please visit

About Novaliq

Novaliq is a pharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first water-free eye drop technology. Novaliq offers an industry-leading portfolio addressing the needs of patients with eye diseases: NOV03 is the first investigational drug in phase 3 to treat evaporative DED associated with Meibomian gland dysfunction in a highly effective way. CyclASol®, 0.1% cyclosporine A in EyeSol®, is an anti-inflammatory and immunomodulating drug developed for the treatment of aqueous deficient DED. NovaTears® water-free eye drops for dry eye have CE certification and are commercialized in Australia/New Zealand by AFT Pharmaceuticals and in Europe as EvoTears® by Ursapharm. Headquartered in Heidelberg/Germany, Novaliq has an office in Cambridge, MA/USA. Long-term shareholder is dievini Hopp BioTech.

Novaliq Completes Enrollment of Second Phase 3 Study for CyclASol® for the Treatment of Dry Eye Disease

Heidelberg, Germany, and Cambridge, MA, August 10, 2021 – Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced the second of two Phase 3 (ESSENCE-2) studies, evaluating the investigational drug CyclASol® to treat the signs and symptoms of dry eye disease DED, has been completely enrolled with a total of 834 participants.

New clinical study shows Novaliq NovaTears®+Omega-3 eye drops is a significantly effective treatment for dry eye disease

NovaTears®+Omega-3, an innovative dry eye treatment in-licensed and distributed in Australia and New Zealand by AFT Pharmaceuticals, is a significantly effective treatment for evaporative Dry Eye Disease (DED), a new clinical study1 has found.

Enrollment of second phase 3 trial for NOV03 completed

LAVAL, QC and HEIDELBERG, Germany, July 7, 2021 /PRNewswire/ — Bausch + Lomb, a leading global eye health business of BauschHealth Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”), and Novaliq GmbH, a biopharmaceutical companyfocusing on first- and best-in-class ocular therapeutics, today announced the second of two Phase 3 (MOJAVE) studies evaluating theinvestigational drug NOV03 (perfluorohexyloctane) as a first-in-class eye drop with a novel mechanism of action to treat the signs andsymptoms of dry eye disease (DED) associated with meibomian gland dysfunction (MGD), has been completely enrolled with a total of622 participants.

Novaliq Announces More than 50% Patients Enrolled in CyclASol® Phase 3 Dry Eye Disease Trial ESSENCE-2

  • Topline results expected in 2nd half 2021; 475 out of a 834 target patients randomized in ESSENCE-2
  • Enrollment for 12-month safety extension trial (ESSENCE-2 OLE) completed
  • Phase 2B/3 Trial ESSENCE-1 Published in Cornea: The Journal of Cornea and External Disease
Heidelberg and Cambridge, MA – April 28, 2021 – Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced that the second Phase 3 clinical trial evaluating CyclASol® to treat the signs and symptoms of dry eye disease (DED) has randomized more than 50% out of 834 targeted patients, with top-line results expected in the 2nd half of 2021.

Betaliq Initiates Enrollment of Phase 2 Clinical Trial For The Treatment of Glaucoma or Ocular Hypertension

Betaliq Initiates Enrollment of Phase 2 Clinical Trial Investigating BTQ-1901-A, BTQ 1901 B and BTQ-1902 For The Treatment of Glaucoma or Ocular Hypertension
TAMPA, FL, UNITED STATES, April 20,2021 / — Betaliq, Inc., a clinical-stage ophthalmic company focused on developing therapies for the treatment of glaucoma, today announced enrollment of the first subject in their Phase 2 clinical trial. Betaliq’s pipeline consists of two preservative-free and water-free glaucoma drug candidates based on Novaliq GmbH’s EyeSol® technology. EyeSol is the worldwide first and only water-free technology for topical ophthalmology products. Two EyeSol based ophthalmic products are currently approved in Europe and Australia and two active INDs are in late-stage development in the United States.